DOI: 10.1161/circ.148.suppl_1.14433 ISSN: 0009-7322

Abstract 14433: The Utility of Fibrinogen-Albumin-Ratio as a Prognostic Biomarker in Coronary Artery Disease Patients: A Comprehensive Meta-Analysis

Mohammad Tanashat, Mostafa Hossam El Din Moawad, Alaa Ramadan, Obieda Altobaishat, Abdallah Abbas, Mahmoud Shalaby, Marwa Elnagar, Mohamed Hendawy
  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Background: Coronary artery diseases (CAD) are considered the leading cause of death and morbidity worldwide. The fibrinogen-to-albumin ratio (FAR), a novel inflammatory indicator, has been investigated to be associated with CAD. However, for CAD patients who received percutaneous coronary intervention (PCI), the predictive significance of the FAR is still unclear.

Objective: This systematic review aimed to investigate the use of FAR as a prognostic biomarker for negative outcomes of CAD.

Methods: Following the PRISMA guidelines, we searched PubMed, Scopus, and Web of Science for eligible articles mentioning the utility of FAR in the prognosis of CAD patients. In conducting our meta-analysis, a random effect model was used. The results were examined using a pooled adjusted hazard ratio or mean difference with a 95% confidence level. The Q statistics and I2 value were used to evaluate heterogeneity. A p-value of equal or less than 0.5 indicated statistically significant results and heterogeneity.

Results: We included 21 studies in our meta-analysis after the screening process. Four studies with a total of 2813 participants reported that the pooled estimates of FAR revealed that CAD patients had higher values compared to non-CAD patients (SMD = 1.23 [0.45, 2.02]; P = 0.002). Our meta-analysis showed that high FAR level was statistically significant associated with increased all-cause mortality, cardiac mortality, and MACE as observed by hazard ratio. Using mean difference, high FAR values were associated with lower LVEF, higher SYNTAX score and no reflow.

Conclusion: FAR can be utilized as a prognostic biomarker in CAD patients to predict poor outcomes.

More from our Archive